DPYSL2 and focal epilepsy: The CRMP2 antagonist, Lacosamide, is specifically used to treat refractory partial epilepsy seizures, by mechanisms that might involve stabilization of neuronal firing through regulation of voltage-gated sodium channels, or inhibition of abnormal axon sprouting [73–75].